Effect of the Serious Illness Care Program in Outpatient Oncology: A Cluster Randomized Clinical Trial | Oncology | JAMA Internal Medicine | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    March 14, 2019

    Effect of the Serious Illness Care Program in Outpatient Oncology: A Cluster Randomized Clinical Trial

    Author Affiliations
    • 1Harvard Medical School, Boston, Massachusetts
    • 2Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts
    • 3Ariadne Labs, Brigham and Women’s Hospital, Harvard T. H. Chan School of Public Health, Boston, Massachusetts
    • 4Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts
    • 5Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, the Netherlands
    • 6Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts
    JAMA Intern Med. 2019;179(6):751-759. doi:10.1001/jamainternmed.2019.0077
    Key Points

    Question  Does a quality-improvement intervention designed to enhance communication between oncology clinicians and patients with advanced cancer improve goal-concordant care, peacefulness, therapeutic alliance, anxiety, and depression?

    Findings  In this cluster randomized clinical trial evaluating use of a communication quality-improvement intervention by 91 clinicians for 278 patients with advanced cancer, results were null with respect to the coprimary outcomes of goal-concordant care and peacefulness for decedents, but there were fewer than expected patients with evaluable coprimary outcomes. However, the trial demonstrated significant reductions in moderate to severe anxiety and depression symptoms among intervention patients in the total population.

    Meaning  This cluster randomized clinical trial highlighted the challenges of measuring outcomes near the end of life among patients with advanced cancer; secondary outcomes of anxiety and depression are important and require further study.


    Importance  High-quality conversations between clinicians and seriously ill patients about values and goals are associated with improved outcomes but occur infrequently.

    Objective  To examine feasibility, acceptability, and effect of a communication quality-improvement intervention (Serious Illness Care Program) on patient outcomes.

    Design, Setting, and Participants  A cluster randomized clinical trial of the Serious Illness Care Program in an outpatient oncology setting was conducted. Patients with advanced cancer (n = 278) and oncology clinicians (n = 91) participated between September 1, 2012, and June 30, 2016. Data analysis was performed from September 1, 2016, to December 27, 2018. All analyses were conducted based on intention to treat.

    Interventions  Tools, training, and system changes.

    Main Outcomes and Measures  The coprimary outcomes included goal-concordant care (Life Priorities) and peacefulness (Peace, Equanimity, and Acceptance in the Cancer Experience questionnaire) at the end of life. Secondary outcomes included therapeutic alliance (Human Connection Scale), anxiety (Generalized Anxiety Disorder 7 scale), depression (Patient Health Questionnaire 9), and survival. Uptake and effectiveness of clinician training, clinician use of the conversation tool, and conversation duration were evaluated.

    Results  Data from 91 clinicians in 41 clusters (72.9% participation; intervention, n = 48; control, n = 43; 52 [57.1%] women) and 278 patients (45.8% participation; intervention, n = 134; control, n = 144; 148 [53.2%] women) were analyzed. Forty-seven clinicians (97.9%) rated the training as effective (mean [SD] score, 4.3 [0.7] of 5.0 possible); of 39 who received a reminder, 34 (87.2%) completed at least 1 conversation (median duration, 19 minutes; range, 5-70). Peacefulness, therapeutic alliance, anxiety, and depression did not differ at baseline. The coprimary outcomes were evaluated in 64 patients; no significant differences were found between the intervention and control groups. However, the trial demonstrated significant reductions in the proportion of patients with moderate to severe anxiety (10.2% vs 5.0%; P = .05) and depression symptoms (20.8% vs 10.6%; P = .04) in the intervention group at 14 weeks after baseline. Anxiety reduction was sustained at 24 weeks (10.4% vs 4.2%; P = .02), but depression reduction was not sustained (17.8% vs 12.5%; P = .31). Survival and therapeutic alliance did not differ between groups.

    Conclusions and Relevance  The results of this cluster randomized clinical trial were null with respect to the coprimary outcomes of goal-concordant care and peacefulness at the end of life. Methodologic challenges for the primary outcomes, including measure selection and sample size, limit the conclusions that can be drawn from the study. However, the significant reductions in anxiety and depression in the intervention group are clinically meaningful and require further study.

    Trial Registration  ClinicalTrials.gov identifier: NCT01786811